ARWR Quote, Financials, Valuation and Earnings

Harmony Biosciences Holdings has a net margin of -- compared to Arrowhead Pharmaceuticals's net margin of 24.78%. Arrowhead Pharmaceuticals's return on equity of -- beat Harmony Biosciences Holdings's return on equity of 23.59%.

Arrowhead Pharmaceuticals has a consensus price target of $47.50, signalling upside risk potential of 150.53%. On the other hand Harmony Biosciences Holdings has an analysts' consensus of $53.88 which suggests that it could grow by 57.53%. Given that Arrowhead Pharmaceuticals has higher upside potential than Harmony Biosciences Holdings, analysts believe Arrowhead Pharmaceuticals is more attractive than Harmony Biosciences Holdings.

Arrowhead Pharmaceuticals has a beta of 0.906, which suggesting that the stock is 9.418% less volatile than S&P 500. In comparison Harmony Biosciences Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Arrowhead Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harmony Biosciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals pays -- of its earnings as a dividend. Harmony Biosciences Holdings pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals quarterly revenues are --, which are smaller than Harmony Biosciences Holdings quarterly revenues of $186M. Arrowhead Pharmaceuticals's net income of -$170.5M is lower than Harmony Biosciences Holdings's net income of $46.1M. Notably, Arrowhead Pharmaceuticals's price-to-earnings ratio is -- while Harmony Biosciences Holdings's PE ratio is 16.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals is 12.50x versus 2.91x for Harmony Biosciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences has a net margin of -- compared to Arrowhead Pharmaceuticals's net margin of -3441.7%. Arrowhead Pharmaceuticals's return on equity of -- beat Avidity Biosciences's return on equity of -30.66%.

Arrowhead Pharmaceuticals has a consensus price target of $47.50, signalling upside risk potential of 150.53%. On the other hand Avidity Biosciences has an analysts' consensus of $68.27 which suggests that it could grow by 126.74%. Given that Arrowhead Pharmaceuticals has higher upside potential than Avidity Biosciences, analysts believe Arrowhead Pharmaceuticals is more attractive than Avidity Biosciences.

Arrowhead Pharmaceuticals has a beta of 0.906, which suggesting that the stock is 9.418% less volatile than S&P 500. In comparison Avidity Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Arrowhead Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals pays -- of its earnings as a dividend. Avidity Biosciences pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals quarterly revenues are --, which are smaller than Avidity Biosciences quarterly revenues of $2.3M. Arrowhead Pharmaceuticals's net income of -$170.5M is lower than Avidity Biosciences's net income of -$80.4M. Notably, Arrowhead Pharmaceuticals's price-to-earnings ratio is -- while Avidity Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals is 12.50x versus 292.86x for Avidity Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Arrowhead Pharmaceuticals's net margin of 7.2%. Arrowhead Pharmaceuticals's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

Arrowhead Pharmaceuticals has a consensus price target of $47.50, signalling upside risk potential of 150.53%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.96 which suggests that it could grow by 53.05%. Given that Arrowhead Pharmaceuticals has higher upside potential than Sarepta Therapeutics, analysts believe Arrowhead Pharmaceuticals is more attractive than Sarepta Therapeutics.

Arrowhead Pharmaceuticals has a beta of 0.906, which suggesting that the stock is 9.418% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Arrowhead Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Arrowhead Pharmaceuticals's net income of -$170.5M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Arrowhead Pharmaceuticals's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 78.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals is 12.50x versus 7.45x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to Arrowhead Pharmaceuticals's net margin of 37.71%. Arrowhead Pharmaceuticals's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

Arrowhead Pharmaceuticals has a consensus price target of $47.50, signalling upside risk potential of 150.53%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.76%. Given that Arrowhead Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Arrowhead Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Arrowhead Pharmaceuticals has a beta of 0.906, which suggesting that the stock is 9.418% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Arrowhead Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Arrowhead Pharmaceuticals's net income of -$170.5M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Arrowhead Pharmaceuticals's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals is 12.50x versus 10.01x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.